Document:

Supply and Manufacturing Agreement

 Exhibit 10.14.1 
 CONFIDENTIAL TREATMENT REQUESTED 
 The confidential portions of this exhibit have been filed separately with the
Securities and Exchange Commission pursuant to a confidential treatment request in accordance with Rule 24b-2 of the Securities and Exchange Act of 1934 as amended. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***. 
 FIRST AMENDMENT 
 TO 
 Supply and Manufacturing Agreement 
 THIS AMENDMENT, dated as of this 24th day of April, 2007, by and between Teikoku Seiyaku Co., Ltd./Teikoku Pharma USA, Inc. (collectively, “TEIKOKU”) and ENDO PHARMACEUTICALS INC.
(“ENDO”). 
 WITNESSETH: 
 WHEREAS, TEIKOKU and ENDO are parties to a Supply and Manufacturing Agreement, dated as of November 23, 1998 (the “Agreement”), by and between and ENDO, pursuant to which TEIKOKU has agreed to
manufacture and supply the Product on behalf of ENDO; and 
 WHEREAS, the parties now wish to amend certain provisions of the Agreement.

 NOW THEREFORE, in consideration of the foregoing and the mutual covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  

	 	1.	Amendment to Section 1.1 (Definition of Adverse Reaction). Section 1.1 shall be deleted and replaced in its entirety with the following: 

“[INTENTIONALLY OMITTED]” 
  

	 	2.	Amendment to Section 1.9 (Definition of Intellectual Property Rights). Section 1.9 shall be deleted and replaced in its entirety with the following:

 “Intellectual Property Rights” means the Patents, including those listed in Exhibit A (as may be amended from time
to time), and Know-How only for the Product owned by or licensed to TEIKOKU which would be infringed by the manufacture, export, import, sale or use of the Product.” 
  

	 	3.	Amendment to Section 1.16 (Definition of Product). Section 1.16 shall be deleted and replaced in its entirety with the following: 

 “Product” means a topical (patch) delivery system, which consists of a formulation of *** lidocaine.” 
  

					
	Confidential	 	Page 1	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	4.	Amendment to Section 2.1(b) (ENDO’s Obligations). A new Section 2.1(b)(ii) shall be added to Section 2.1(b) as follows: 

 “(ii) ENDO is responsible for certifying that facilities and operations of the Contract Packager (as defined in Section 2.4) are in compliance
with current GMP. Further, ENDO will provide TEIKOKU with a GMP confirmation letter from Contract Packager.” 
  

	 	5.	Amendment to Section 2.2(a) (Supply of the Product). A new sentence shall be added to Section 2.2(a) as follows: 

 “TEIKOKU hereby grants ENDO an exclusive (even as to TEIKOKU) license to Intellectual Property Rights to, use, sell, or offer for sale (but not make
or have made), the Product in the Territory; it being understood that should Endo become the sole and exclusive distributor of *** this grant shall apply thereto as well; provided that Know-How shall be licensed to ENDO
hereunder on a non-exclusive basis; and provided further that notwithstanding the foregoing TEIKOKU shall not, and shall not permit any third party to, use, sell or offer to sell in the Territory the Product manufactured by utilizing the
Know-How. 
  

	 	6.	Amendment to Section 2.2(b) (Supply of the Product). Section 2.2(b)(iv) shall be deleted and replaced in its entirety with the following: 

“(iv) Product Firm Orders. No later than the 15th day of each month, ENDO will provide to TEIKOKU USA a firm purchase order for the next succeeding month based on the then current monthly forecast,
which is *** months prior to the initial delivery date stated on such purchase order. In an effort to more accurately forecast required Product, ENDO will provide, on a monthly basis, prior to the 15th of each month, a “Proposed Monthly Forecast / Ordering Cycle” to enable TEIKOKU JAPAN to plan raw material purchases and manufacturing
schedules. The Proposed Monthly Forecast will include (1) current firm purchase orders for the next succeeding *** month period, (2) estimated quantities of Product needed for the next following *** months, (3) and
planned orders of Product for an additional *** months for a total covering *** months. The firm purchase order each month is guaranteed to be not less than *** or more than *** of the previous month’s estimate.
TEIKOKU understands that the estimate and planned figures will be adjusted monthly to more accurately predict quantities of Product needed in succeeding months. In addition, ENDO hereby guarantees TEIKOKU’s purchase of bulk lidocaine for up to
*** patches. It is understood that when ENDO orders approach *** patches, TEIKOKU will request a renewal of this guarantee for the purchase of bulk lidocaine.” 
  

					
	Confidential	 	Page 2	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	7.	Amendment to Section 2.2(b) (Supply of the Product). The following new Section 2.2(b)(vii) shall be added to the Agreement: 

 “(iv) Delivery Schedule. Due to the large quantities of Product delivered for each firm purchase order, TEIKOKU understands that the delivery dates
indicated on firm purchase orders are approximate dates, and with advance notice and approval, TEIKOKU can deliver Product earlier than the “Required Date” stated on the purchase order. It is also understood by ENDO and TEIKOKU that any
one purchase order will require three, four or more separate deliveries of Product depending on the quantities ordered.” 
  

	 	8.	Amendment to Section 2.3(c) (Adverse Drug Reactions/Product Complaints). Section 2.3(c) shall be deleted and replaced in its entirety with the following:

 “[INTENTIONALLY OMITTED]” 
  

	 	9.	New Section 2.3(d) (NDA Maintenance). A new Section 2.3(d) shall be added to the Agreement as follows: 

 “(d) NDA Maintenance. ENDO and TEIKOKU shall collaborate to maintain the NDA properly. For preparation of the Annual
Report, QA/Regulatory personnel from each company will meet to review any packaging changes implemented or pending at such time. If, after filing the Annual Report, questions are raised by the FDA, both parties will collaborate to answer such
questions and ENDO agrees to use its reasonable best efforts to provide to Teikoku whatever data is required to resolve such questions.” 
  

	 	10.	Amendment to Section 2.4 (Payments). The following shall be added to the end of 2.4(a) as follows: 

 “Effective with ENDO’s receipt of the first shipment of QA-released commercial Product
for sale in the U.S. after January 1, 2007, the prices listed below shall apply and remain in effect until ***; thereafter such prices shall be adjusted on December 31st of each of *** (each, an “Adjustment Date”) by the Price Index (as defined below). Specifically, on each Adjustment Date, the parties shall
multiply the price for the Product by a fraction, the numerator of which is the average of the annual Price Index for the *** preceding the Adjustment Date, and the denominator is the Price Index for the month of December of the year such
adjustment is occurring. “Price Index” means the Producer Price Index – Pharmaceutical Preparations, 1982-1984 = 100.* 
  

					
	Confidential	 	Page 3	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 “Pricing of Bulk Lidoderm Brand Product Package from 2007 through *** 
  

			
	 “Annual Quantity of Envelopes
	 	 Unit Cost per Bulk Product Envelope
 CIIF, Endo’s Designated Bulk Package
 Receiving Center, USA

	 *** patches ordered
	 	***
	 *** patches ordered
	 	***

 *** 
 “ENDO agrees to purchase a *** patches per year for each year in the remaining Term of this Agreement *** (the “***”); provided that, in the event that ENDO is prevented from
marketing and/or selling the Product in the U.S. due to external regulatory or legal reasons, ENDO and TEIKOKU shall negotiate in good faith to establish a new *** purchase requirement and unit price for the Product. 
 “ENDO agrees that the prices set forth in this Section 2.4 are for bulk delivery by TEIKOKU of Product (Lidoderm patches in single-patch
envelopes). ENDO will, at its own expense contract separately with a contract packager for the cartoning or other packaging work of the bulk Lidoderm envelopes (such contract packager, the “Contract Packager”).” 
 “After ***, either party has the right to end the parties’ exclusivity obligations relating to the Product upon thirty
(30) day’s written notice within sixty (60) days of the below-referenced shortfall if, at the end of any calendar year, Endo has failed to purchase *** million patches and has not corrected this shortfall within forty-five
(45) days of receiving written notice of such shortfall from Teikoku.” 
 “After ***, if (a) the TEIKOKU Patent has
not then expired or been found invalid or unenforceable and (b) there are *** on the market in the Territory *** and (c) at the end of any calendar year, ENDO has purchased less 

	*	For example: If the annual Price Index is ***, then *** adjustment would be ***. In such case, *** pricing would then be as follows(illustration only):

  

			
	 Annual Quantity of Envelopes
	 	 Unit Cost per Bulk Product Envelope
 CIIF, Endo’s Designated Bulk Package
 Receiving Center, USA

	First *** patches ordered	 	***
	 Over *** patches ordered
	 	***

  

					
	Confidential	 	Page 4	 	

 
CONFIDENTIAL TREATMENT REQUESTED 
 than
*** patches and has not corrected this shortfall within forty-five (45) days of receiving written notice of such shortfall from Teikoku, then TEIKOKU shall have the right to end its exclusivity obligations to the Product upon thirty
(30) day’s written notice within sixty (60) days of the above-referenced shortfall.” 
  

	 	11.	Amendment to Section 2.4 (Payments). A new Section 2.4(c) shall be added to the Agreement as follows: 

 “(c) Following cessation of ENDO’s obligation to pay royalties to HIND under Sections 4.1 (a), (b) and (c) of the Sole and Exclusive
License Agreement, dated as of November 23, 1998, as amended, between HIND and ENDO, ENDO agrees to pay to TEIKOKU an annual royalty of (i) *** f Net Sales per Fiscal Year of the brand Product in the Territory for the term of this
Agreement and (ii) *** of Net Sales per Fiscal Year *** in the Territory for the term of this Agreement. 
 “For
purposes of this Section 2.4(c), “Net Sales” shall be defined as the gross amount invoiced by ENDO or its sublicensees or Affiliates for the sale or other disposition of Licensed Product to independent third parties less the following
amounts: (i) normal and customary trade, cash and quantity discounts actually given, credits, price adjustments or allowances for damaged products, returns or rejections of products; (ii) chargeback payments and rebates (or the equivalent
thereof) granted to group purchasing organizations, managed health care organizations or to federal, state/provincial, local and other governments, including their agencies, or to trade customers; (iii) freight, shipping insurance and other
transportation expenses directly related to the sale (if actually borne by ENDO, its Affiliates or sublicenses without reimbursement from any third party); (iv) required distribution commissions/fees payable to any third party providing
distribution services to ENDO; (v) expired Product; (vi) sales, value-added, excise taxes, tariffs and duties, and other taxes and government charges directly related to the sale, to the extent that such items are included in the gross
invoice price and actually borne by ENDO, its Affiliates or sublicensees without reimbursement from any third party (but not including taxes assessed against the income derived from such sale); and (vii) provisions for actual uncollectible
accounts determined in accordance with U.S. generally accepted accounting practices, consistently applied to all products of ENDO. “Fiscal Year” shall be defined as any twelve (12) month period commencing on the first day of January
of any year.” 
  

					
	Confidential	 	Page 5	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	12.	Amendment to Section 2.5 (Product Shipments). The following shall be added to the end of Section 2.5: 

 “Notwithstanding the foregoing, the parties agree that (1) TEIKOKU will supply Bulk Product to ENDO at ENDO’s designated bulk Product
receiving center as may be designated as such by ENDO in writing to TEIKOKU from time to time; (2) after TEIKOKU is notified by ENDO that the shipment of bulk Product has reached ENDO’s designated bulk Product receiving center (i.e.,
***), TEIKOKU will issue to ENDO a commercial invoice in accordance with this Agreement; (3) upon issuance of such commercial invoice to ENDO, ownership of the Product will be transferred from TEIKOKU to ENDO; and (4) ENDO is
responsible for all costs of final packaging and any actual losses related thereto.” As of April 24, 2007, “Bulk Product” means *** of Product in a bulk shipping box with one envelope containing one Product.”

  

	 	13.	New Section 4.3. A new Section 4.3 shall be added to the Agreement as follows: 

 “4.3 In the event ENDO exercises its option for a license to market, sell and promote the Product in Canada and Mexico under the Related Agreement,
TEIKOKU hereby grants ENDO an exclusive (even as to TEIKOKU) license to Intellectual Property Rights in such countries, to use, market, sell, or offer for sale, the Product it being understood that should Endo become the sole and exclusive
distributor of *** in such countries, this grant shall apply thereto as well.” 
  

	 	14.	Amendment to Section VI (TERM). Section VI shall be deleted and replaced in its entirety with the following: 

 “VI. Term 
 This Agreement shall
begin on the date written above and not expire until December 31, 2021, unless terminated in accordance herewith. After December 31, 2021, this Agreement shall be automatically renewed on the first day of January each year unless
(i) the parties agree to terminate this Agreement upon mutual written agreement authorized and signed by both parties or (ii) a party terminates this Agreement with 180-day written notice to the other party, which notice shall not in any
event be effective prior to July 1, 2022. If Endo is the terminating party pursuant to clause (ii) of the preceding sentence, Endo shall be responsible for any existing firm order outstanding on the effective termination date.
Notwithstanding the foregoing, the parties may terminate this Agreement upon mutual written agreement authorized and signed by both parties at any time. 
  

					
	Confidential	 	Page 6	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	15.	Amendment to Section VII (TERMINATION). A new subsection (d) under Section VII shall be added as follows: 

 “(d) Either party may terminate this Agreement in the event that ENDO fails to purchase the *** or each year after *** (e.g.,
***) ***; provided that this Agreement may only be terminated under this subsection (d) upon thirty (30) days’ written notice; provided further that in the event that ENDO is prevented from marketing and/or
selling the Product in the U.S. due to external regulatory or legal reasons, ENDO and TEIKOKU shall negotiate in good faith to establish a new minimum purchase requirement for this subsection (d) and unit price for the Product. 
  

	 	16.	Amendment to Section X (INDEMNIFICATION). Section 10.3 shall be added to the Agreement as follows: 

 “10.3 ENDO shall indemnify, defend, and hold harmless TEIKOKU, its officers, agents, Affiliates, subsidiaries, parent companies, and employees, from
and against any and all loss, damage, claim, injury, cost of expense, including reasonable attorneys’ fees and expenses of litigation, in connection with any illness or personal injury, including death, or property damage, that arises out of:
(1) any use, marketing, promotion, sale, final packaging, or distribution of the Product in the Territory; (2) the negligence or willful misconduct of ENDO; or (3) breach of the terms of this Agreement by ENDO, provided
however, ENDO shall not be obligated to indemnify TEIKOKU to the extent that any loss, damage, claim, injury, cost or expense arises out of TEIKOKU’s negligence, willful misconduct, latent Product defects, or breach of this
Agreement.” 
  

	 	17.	Amendment to Section X (INDEMNIFICATION). New Sections 10.4 and 10.5 shall be added to the Agreement as follows: 

 “10.4 Mutual Indemnity and Shared Liability. In the event claims, suits, and demands for liability, damages, losses, costs and expenses
(including the costs and expenses of attorneys and other professionals) (collectively, “Damages”) arise out of third party claims which are subject to indemnification by Teikoku under Section 10.1 or 10.2 and also subject to
indemnification by Endo under Section 10.3, then the parties shall indemnify each other to the extent of their respective liability for the Damages. Any Damages that arise out of third party claims arising out of or resulting from the alleged
or actual inaccuracy of the package insert or label of the Product shall be shared equally by the parties. In the event that the parties cannot agree to their respective indemnity obligations under this Agreement, a party shall be free at any time
to resolve the respective indemnity obligations of the parties under this Section X pursuant to the arbitration provisions set forth in Section XVI. 
  

					
	Confidential	 	Page 7	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 “10.5 Conditions of Indemnification. 
 (a) Upon receipt by a party or its directors, officers, agents, Affiliates, subsidiaries, parent companies and employees seeking indemnification under this Agreement (an “Indemnified Party”) of notice of any
threatened or filed action, suit, proceeding, claim, demand or assessment against such Indemnified Party which might give rise to Damages, such party shall promptly provide written notice thereof to the party from which indemnification is sought
(the “Indemnifying Party”) indicating the nature of the claim and the basis therefor (within no more than one week upon the receipt of any complaint and two weeks upon receipt of any claim letter). If ENDO receives notice of any such
claim, suit or demand, ENDO shall provide written notice thereof by facsimile or e-mail to TEIKOKU as set forth in Section XVII and to the offices of ***. If TEIKOKU receives notice of any such claim, suit or demand, TEIKOKU shall provide written
notice thereof by facsimile or e-mail to ENDO as set forth in Section XVII and to the offices of ***. 
 (b) The Indemnified
Party shall permit the Indemnifying Party to assume direction and control of the defense of claims resulting therefrom (including the right to settle such claims at the sole discretion of the Indemnifying Party, but subject to the approval of the
other party, not to be unreasonably withheld, if such settlement provides for injunctive or other non-monetary relief affecting the Indemnitees or any admission of liability). In the event either (1) the claim, suit or demand is covered by the
mutual indemnity or shared liability set forth in Section 10.4 or (2) such claim, suit or demand names both ENDO and TEIKOKU, ENDO agrees to assume the direction and control of the defense of claims resulting therefrom; provided that
ENDO shall have the right to settle such claims at its sole discretion, but subject to the written approval of TEIKOKU, not to be unreasonably withheld; provided further that ENDO and TEIKOKU shall share equally in the cost of such
defense and any settlement or judgment associated therewith. 
 (c) The Indemnified Party agrees to cooperate as requested (at
the expense of the Indemnifying Party) in the defense of such claims. The Indemnified Party further agrees that if discovery reveals an independent basis for indemnification hereunder by the Indemnified Party, the Indemnifying Party shall be
permitted to re-tender defense of such claim to the Indemnified Party. In any event, each party shall supply periodic reports to the other party regarding the status of all claims, subject, if necessary, to the parties’ entering into a joint
defense agreement. 
  

					
	Confidential	 	Page 8	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	18.	Amendment to Section XVII (NOTICES). Section XVII shall be deleted and replaced in its entirety with the following: 

 “All notices, requests or other communication provided for or permitted hereunder shall be given in writing and shall be hand delivered or sent by
facsimile, reputable courier or by registered or certified mail, postage prepaid, return receipt requested, to the addresses set forth below, or to such other address as either party may inform the other of in writing. Notices will be deemed
delivered on the earliest of transmission by facsimile, actual receipt or seven days after mailing as set forth herein. 
 If to TEIKOKU:

 Attention: President & CEO 
 Teikoku Pharma USA, Inc. 
 1718 Ringwood Avenue 
 San Jose, CA 95131-1711 
 Tel: (408) 501-1800 
 Fax:(408) 501-1900 
 With a copy to:

 Attention : Manager, International Division 
 Teikoku Seiyaku Co., Ltd. 
 567 Sanbonmatsu 
 Higashikagawa, 
 Kagawa 769 2695 

Japan 
 Tel: 81.879.25.2221 

Fax: 81.879.24.1555 
 If to ENDO:

 Endo Pharmaceuticals Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317 USA 
 Attention: Chief Executive Officer 
 Tel: (610) 558-9800 
 Fax: (610) 558-9682 
 With a copy to:

 Endo Pharmaceuticals Inc. 
 100 Endo Boulevard 
 Chadds Ford, PA 19317 USA 
 Attention: Chief Legal Officer 
 Tel: (610) 558-9800 
 Fax: (610) 558-9684” 
  

					
	Confidential	 	Page 9	 	

 CONFIDENTIAL TREATMENT REQUESTED 
  

	 	19.	Amendment to Section XVIII (ASSIGNMENT). The following new sentence shall be added to the end of Section XVIII: 

 “One condition for any consent sought hereunder shall be that the assignee or successor shall assume the obligations of the assignor or transferor
under this Agreement; it being understood that an assignee or successor of ENDO shall source the Product from TEIKOKU so long as TEIKOKU holds the NDA therefor.” 
  

	 	20.	Amendment to Section XXIII (ENTIRETY). The first sentence of Section XXIII shall be deleted and replaced in its entirety with the following: 

 “This Agreement, together with its attached Exhibits, that certain safety agreement, dated as of January 22, 2004, between the parties, that
certain quality agreement, dated as of December 20, 2006, that certain side letter, dated as of April 20, 2007, and that certain side letter, dated as of April 24, 2007, and between the parties, all as may be amended from time to
time, constitute the entire agreement between ENDO and TEIKOKU with respect to the subject matter hereof and supersedes all prior and/or contemporaneous agreements and understandings, whether oral, written or in any other medium, that might exist
between the parties with relation to the subject matter hereof.” 
  

	 	21.	New Section XXIV. A new Section XXIV shall be added to the Agreement as follows: 

 XXIV. ENDO Challenges to Patents. 
 ENDO shall not seek a court ruling that the Patents are invalid. Moreover, TEIKOKU shall have the right to terminate this Agreement if ENDO challenges the Patents in court. Finally, ENDO shall pay TEIKOKU’s attorneys’
fees and costs in defending any ENDO court challenge to the validity of the Patents if TEIKOKU should prevail in the court challenge. 
  

	 	22.	New Section XXV. A new Section XXV shall be added to the Agreement as follows: 

 XXV. Books and Records; Audit Rights. 
 (a) Audit Right. ENDO shall keep full and true books of
accounts and other records in sufficient detail so that the royalties payable hereunder 
  

					
	Confidential	 	Page 10	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 can be properly ascertained. ENDO shall, at the request of TEIKOKU, permit a U.S. nationally recognized independent certified public accountant selected
by TEIKOKU (but not the accountant that conducts or has within the past three years conducted the audit of TEIKOKU’s financial statements) to have access during ordinary business hours, to such books and records as may be necessary to determine
the correctness of any payment report or payment made under this Agreement or to obtain information as to royalties payable in case of failure to report or pay pursuant to the terms of this Agreement. The auditor will execute a written
confidentiality agreement with ENDO and will disclose to TEIKOKU only the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement. The auditor will send a copy of the report to ENDO at the same time it is
sent to TEIKOKU. Such examination shall be conducted (a) after at least thirty (30) days’ prior written notice from TEIKOKU, (b) at the facility(ies) where such books and records are maintained, (c) without disruption to
operations of ENDO (to the extent reasonably practicable, such examination shall be completed within 30 business days), and (d) no more frequently than once in any calendar year. TEIKOKU shall be responsible for expenses for the independent
certified public accountant, except that ENDO shall reimburse TEIKOKU up to *** or such independent accountant documented services if the independent accountant determines the royalties paid by ENDO to TEIKOKU are less than *** of the
amount actually owed for the period of the audit and such determination is finally resolved in favor of TEIKOKU pursuant to clause (c) below if contested by ENDO. All inspections made hereunder shall be made no later than *** after the
royalty that is the subject of the investigation was due, and all royalty payments not so audited within *** will be deemed accurate and in accordance with the terms of this Agreement. 
 (b) Underpayment or Overpayment. If as a result of any audit pursuant to subsection (a) it is shown that ENDO’s royalty payments under
this Agreement with respect to the period of time audited were less than the amount that should have been paid pursuant to this Agreement, then ENDO shall, within thirty (30) days after TEIKOKU’s demand therefor, either pay TEIKOKU the
amount of such shortfall or proceed to the dispute resolution mechanism set forth in subsection (c) below. If as a result of any audit pursuant to subsection (a) it is shown that ENDO’s royalty payments under this Agreement with
respect to the period of time audited exceeded the amount that should have been paid pursuant to this Agreement, then TEIKOKU shall, within thirty (30) days after ENDO’s demand therefor, either pay ENDO or agree to in writing to credit
ENDO against ENDO’s next required royalty payment the amount of such excess or proceed to the dispute resolution mechanism set forth in subsection (c) below. 
  

					
	Confidential	 	Page 11	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 (c) Resolution of Dispute as to Audit. In the event that the parties do not agree on the amount of overpayment or underpayment, within thirty
(30) days, each party shall select an independent public accounting firm (and each party shall pay the costs of its own accounting firm), which shall meet and discuss the amount in dispute and other related matters within thirty (30) days
thereafter. If such independent public accounting firms cannot agree on a resolution mutually agreeable to the parties, such independent public accounting firms shall, within thirty (30) days after such selection, appoint a third independent
public accounting firm which shall resolve the issue within thirty (30) days after its selection, and the parties shall equally share the costs of such accounting firm. The recommendation of the third independent public accounting firm shall be
final and binding upon the parties. A judgment on such firm’s disposition may be entered in any court having jurisdiction over the parties. Notwithstanding anything to the contrary herein, the resolution of any dispute under this Section XXV
shall be made under this subsection (c) instead and in lieu of Section XVI. The preceding sentence shall not preclude the application of Section XVI to any contract interpretation issue (as compared to an accounting issue which would be
precluded from determination under Section XVI). 
  

	 	23.	Exhibit A  

 Exhibit A to the Agreement shall be
deleted in its entirety and replaced with Exhibit A to this Amendment. 
  

	 	24.	Capitalized Terms 

 Capitalized terms, whenever used
in this Amendment, shall have the meanings ascribed to them in the Agreement. 
  

	 	25.	Conflict. 

 This Amendment or the relevant side
letter will govern if either document conflicts with any provision of the Agreement. The relevant side letter will govern any conflict between the side letter and the Amendment. 
  

	 	26.	Effectiveness of the Agreement 

 Except as amended
hereinabove, all other terms and provisions of the Agreement shall remain in full force and effect. 
  

					
	Confidential	 	Page 12	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 IN WITNESS WHEREOF, this Amendment has been executed by the authorized officers of the parties hereto as of the date and year first above written. 
  

			
	TEIKOKU SEIYAKU CO., LTD.
		
	BY:	 	 /S/ SHOSAKU MURAYAMA

	Name:	 	Shosaku Murayama
	Title:	 	President & CEO
	
	TEIKOKU PHARMA USA, INC.
		
	BY:	 	 /S/ MASAHISA KITAGAWA

	Name:	 	Masahisa Kitagawa
	Title:	 	President & CEO
	
	ENDO PHARMACEUTICALS INC.
		
	BY:	 	 /S/ PETER A. LANKAU

	Name:	 	Peter A. Lankau
	Title:	 	President & CEO

  

					
	Confidential	 	Page 13	 	

 CONFIDENTIAL TREATMENT REQUESTED 
 Exhibit A 
 LIST OF TEIKOKU PATENTS, PATENT APPLICATIONS AND KNOW-HOW

 *** 
  

					
	Confidential	 	Page 14Executive Severance Plan

 Exhibit 10.1 
 EMBARQ CORPORATION 
 EXECUTIVE SEVERANCE PLAN 

					
	 ARTICLE I        PURPOSE AND TERM OF PLAN
	  	1
			
	 Section 1.01
	 	Purpose of the Plan	  	1
			
	 Section 1.02
	 	Term of the Plan	  	1
		
	 ARTICLE II      DEFINITIONS
	  	1
			
	 Section 2.01
	 	“Base Salary”	  	1
			
	 Section 2.02
	 	“Board”	  	1
			
	 Section 2.03
	 	“Cause”	  	1
			
	 Section 2.04
	 	“Change in Control”	  	1
			
	 Section 2.05
	 	“CIC Termination”	  	3
			
	 Section 2.06
	 	“COBRA”	  	3
			
	 Section 2.07
	 	“Code”	  	3
			
	 Section 2.08
	 	“Committee”	  	3
			
	 Section 2.09
	 	“Company”	  	3
			
	 Section 2.10
	 	“Competitive Employment”	  	3
			
	 Section 2.11
	 	“Competitor”	  	4
			
	 Section 2.12
	 	“Effective Date”	  	4
			
	 Section 2.13
	 	“Eligible Employee”	  	4
			
	 Section 2.14
	 	“Employee”	  	4
			
	 Section 2.16
	 	“ERISA”	  	5
			
	 Section 2.17
	 	“Exchange Act”	  	5
			
	 Section 2.18
	 	Good Reason Resignation”	  	5
			
	 Section 2.19
	 	“Involuntary Termination”	  	5
			
	 Section 2.20
	 	“Non-CIC Termination”	  	6
			
	 Section 2.21
	 	“Non-Comparable Position”	  	6
			
	 Section 2.22
	 	“Non-Compete Period”	  	6
			
	 Section 2.23
	 	“Non Executive Separation Plan”	  	6
			
	 Section 2.24
	 	“Participant”	  	6
			
	 Section 2.25
	 	“Permanent Disability”	  	6
			
	 Section 2.26
	 	“Plan”	  	6
			
	 Section 2.27
	 	“Plan Administrator”	  	6
			
	 Section 2.28
	 	“Release”	  	6
			
	 Section 2.29
	 	“Service”	  	7

  

 i 

					
	 Section 2.30
	 	“Severance Benefit”	  	7
			
	 Section 2.31
	 	“Severance Period”	  	7
			
	 Section 2.32
	 	“Specified Employee”	  	7
			
	 Section 2.33
	 	“Subsidiary”	  	7
			
	 Section 2.34
	 	“Termination Date”	  	7
			
	 Section 2.35
	 	“Voluntary Resignation”	  	7
			
	 Section 2.36
	 	“Year of Service”	  	7
		
	 ARTICLE III     PARTICIPATION AND ELIGIBILITY FOR BENEFITS
	  	7
			
	 Section 3.01
	 	Participation	  	7
			
	 Section 3.02
	 	Conditions	  	8
		
	 ARTICLE IV     DETERMINATION OF SEVERANCE BENEFITS
	  	8
			
	 Section 4.01
	 	Non-CIC Termination	  	8
			
	 Section 4.02
	 	CIC Termination	  	10
			
	 Section 4.03
	 	Voluntary Resignation; Termination for Death or Permanent Disability	  	11
			
	 Section 4.04
	 	Termination for Cause	  	11
			
	 Section 4.05
	 	Approved Military Leave	  	11
			
	 Section 4.06
	 	Reduction of Severance Benefits	  	12
		
	 ARTICLE V      METHOD OF PAYMENT AND LIMITATION ON BENEFITS
	  	12
			
	 Section 5.01
	 	Method of Payment	  	12
			
	 Section 5.02
	 	409(A) Delay.	  	12
			
	 Section 5.03
	 	Limitation on Benefits	  	13
		
	 ARTICLE VI     RESTRICTIVE COVENANTS
	  	13
			
	 Section 6.01
	 	Principles of Business Conduct.	  	13
			
	 Section 6.02
	 	Proprietary Information	  	13
			
	 Section 6.03
	 	Non-Competition	  	14
			
	 Section 6.04
	 	Inducement of Employees, Customers and Others	  	14
			
	 Section 6.05
	 	No Adverse Actions	  	15
			
	 Section 6.06
	 	Return of Property	  	15
			
	 Section 6.07
	 	Non-Disparagement	  	15
			
	 Section 6.08
	 	Assistance with Claims	  	15
			
	 Section 6.09
	 	Reasonableness	  	16
			
	 Section 6.10
	 	Equitable Relief	  	16

  

 ii 

					
	 Section 6.11
	 	Survival of Provisions	  	16
		
	 ARTICLE VII    COMMITTEE; PLAN ADMINISTRATOR
	  	17
			
	 Section 7.01
	 	Authority and Duties	  	17
			
	 Section 7.02
	 	Compensation of the Plan Administrator and the Committee	  	17
			
	 Section 7.03
	 	Records, Reporting and Disclosure	  	17
			
	 Section 7.04
	 	Discretion	  	17
		
	 ARTICLE VIII   AMENDMENT, SUSPENSION AND TERMINATION
	  	17
			
	 Section 8.01
	 	Amendment, Suspension and Termination	  	17
			
	 Section 8.02
	 	Continuation of Plan following a Change in Control	  	18
		
	 ARTICLE IX     CLAIMS PROCEDURES
	  	18
			
	 Section 9.01
	 	Claims	  	18
			
	 Section 9.02
	 	Initial Claim	  	18
			
	 Section 9.03
	 	Appeals of Denied Administrative Claims	  	19
			
	 Section 9.04
	 	Appointment of the Named Appeals Fiduciary	  	19
		
	 ARTICLE X      MISCELLANEOUS
	  	20
			
	 Section 10.01
	 	Waiver of Jury Trial	  	20
			
	 Section 10.02
	 	Forum Selection	  	20
			
	 Section 10.03
	 	Nonalienation of Benefits	  	20
			
	 Section 10.04
	 	Notices	  	20
			
	 Section 10.05
	 	No Mitigation	  	20
			
	 Section 10.06
	 	No Contract of Employment	  	21
			
	 Section 10.07
	 	Severability of Provisions	  	21
			
	 Section 10.08
	 	Headings and Captions	  	21
			
	 Section 10.09
	 	Gender and Number	  	21
			
	 Section 10.10
	 	Unfunded Plan	  	21
			
	 Section 10.11
	 	Payments to Incompetent Persons	  	21
			
	 Section 10.12
	 	Lost Payees	  	21
			
	 Section 10.14
	 	Controlling Law	  	21
		
	 EXHIBIT A    Participation Agreement
	  	A
			
	 Release
	 		  	1
			
	 Arbitration Provision
	 		  	1

  

 iii 

 ARTICLE I 
 PURPOSE AND TERM OF PLAN 
 Section 1.01 Purpose of the Plan. The purposes
of the Plan are to attract, retain and motivate Eligible Employees upon whom, in large measure, the substantial progress, growth and profitability of the Company depends, as well as, to provide them with a measure of financial protection and
assistance in the transition from Embarq employment in the event the Eligible Employee’s employment with the Company or a Subsidiary is terminated due to a Non-CIC Termination or a CIC Termination. The Plan is not intended to be an
“employee pension benefit plan” or “pension plan” within the meaning of section 3(2) of ERISA. Rather, this Plan is intended to be a “welfare benefit plan” within the meaning of Section 3(1) of ERISA and to meet
the descriptive requirements of a plan constituting a “severance pay plan” within the meaning of regulations published by the Secretary of Labor at Title 29, CFR, section 2510.3-2(b). Accordingly, the benefits paid by the Plan are not
deferred compensation and no employee shall have a vested right to such benefits. 
 Section 1.02 Term of the Plan. The
Plan shall generally be effective as of the Effective Date. The Plan supersedes, and does not duplicate, the provisions of the Non-Executive Separation Plan in any case in which an Eligible Employee would otherwise be entitled to severance or
related benefits under both this Plan and the Non-Executive Separation Plan arising out of the Eligible Employee’s Non-CIC Termination. Moreover, this Plan supersedes any other plan, program, arrangement or agreement providing an Eligible
Employee with severance or related benefits, including the Non Executive Separation Plan, with respect to an Eligible Employee’s CIC Termination or Non-CIC Termination to the extent provided in Section 3.01. The Plan shall continue until
terminated pursuant to Article VIII of the Plan. 
 ARTICLE II 
 DEFINITIONS 
 Section 2.01 “Base Salary”
means the annual rate of base salary in effect on the Participant’s Termination Date or the date of the Change in Control, if higher. 
 Section 2.02 “Board” means the Board of Directors of the Company, or any successor thereto, or a committee thereof specifically designated for purposes of making determinations hereunder. 
 Section 2.03 “Cause” means an Eligible Employee’s (i) willful and continued failure to substantially perform his
or her duties, (ii) willfully engaging in conduct that is a serious violation of the Employer’s Principles of Business Conduct, (iii) willfully engaging in conduct that is demonstrably and materially injurious to the Employer or
(iv) willful violation of any of the restrictive covenants found in Article VI. The Committee shall determine Cause. 
  

 1 

 Section 2.04 “Change in Control” means any of the following events:

 (a) the acquisition , directly or indirectly, by any “person” or “group” (as those terms are defined in sections
3(a)(9), 13(d), and 14(d) of the Exchange Act and the rules thereunder, including Rule 13d-5(b)) of “beneficial ownership” (as determined pursuant to Rule 13d-3 under the Exchange Act) of securities entitled to vote generally in the
election of directors (‘voting securities”) of the Company that represent 30% or more of the combined voting power of the Company’s then outstanding voting securities, other than 
 (i) an acquisition by a trustee or other fiduciary holding securities under any employee benefit plan (or related trust) sponsored or maintained by the
Company or any person controlled by the Company or by any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company, or 
 (ii) an acquisition of voting securities by the Company or a corporation owned, directly or indirectly, by the stockholders of at least 50% of the
voting power of the Company’s then outstanding securities in substantially the same proportions as their ownership of stock of the Company, or 
 (iii) an acquisition of voting securities pursuant to a transaction described in Section 2.04(c) below that would not be a Change in Control under Section 2.04(c); 
 (b) a change in the composition of the Board that causes less than a majority of the directors of the Company to be directors that meet one or more of
the following descriptions: 
 (i) a director who has been a director of the Company for a continuous period of at last 24 months (or, if
less, since the date the shares of Company common stock were listed on the New York Stock Exchange) or, 
 (ii) a director whose election or
nomination as a director was approved by a vote of at least two-thirds of the then directors described in subsections 2.04(b)(i), (ii) or (iii) by prior nomination or election, but excluding, for the purpose of this subsection (ii), any
director whose initial assumption to office occurred as a result of an actual or threatened (y) election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on
behalf of a person or group other than the Board or (z) tender offer, merger, sale of substantially all of the Company’s assets, consolidation, reorganization or business combination that would be a Change in Control under
Section 2.04(c) on consummation thereof, or 
 (iii) who were serving on the Board as result of the consummation of a transaction
described in Section 2.04(c) that would not be a Change in Control under Section 2.04(c); 
 (c) the consummation by the Company
(whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of 
 (i) a consolidation,
merger, reorganization or business combination or 
  

 2 

 (ii) a sale or disposition of all or substantially all of the Company’s assets or 
 (iii) the acquisition of assets or stock of another entity, 
 in each case, other than in a transaction, (x) that results in the Company’s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by
being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company’s assets or
otherwise succeeds to the business of the Company (the Company or such person, the “Successor Entity”)) directly or indirectly, at least 50% of the combined voting power of the Successor Entity’s outstanding voting securities
immediately after the transaction and (y) after which more than 50% of the members of the Board of the Successor Entity were members of the Board at the time of the Board’s approval of the transaction or other action of the Board approving
the transaction (or whose election or nomination was approved by a vote of at least two-thirds of the members who were members of the Board at that time), and (z) after which no person or group beneficially owns voting securities representing
30% or more of the combined voting power of the Successor Entity; provided, however, no person or group shall be treated for purposes of this subsection (z) as beneficially owning 30% or more of combined voting power of the Successor Entity
solely as a result of the voting power held in the Company before the consummation of the transaction; or 
 (d) a liquidation or dissolution
of the Company other than in connection with a transaction described in subsection 2.04(c) above that would not be a Change in Control thereunder. 
 Section 2.05 “CIC Termination” means an Eligible Employee’s Involuntary Termination or Good Reason Resignation that occurs within 6 months before or one year after the date of a Change in Control.

 Section 2.06 “COBRA” means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended.

 Section 2.07 “Code” means the Internal Revenue Code of 1986, as amended. 
 Section 2.08 “Committee” means the Compensation Committee of the Board or such other committee appointed by the Board to
assist the Company in making determinations required under the Plan in accordance with its terms. The “Committee” may delegate its authority under the Plan to one or more individuals or another committee which may or may not include
members of the Board. 
 Section 2.09 “Company” means Embarq Corporation and any successor thereto. 

Section 2.10 “Competitive Employment” means the direct or indirect performance of duties or responsibilities (whether
paid or unpaid and whether as a consultant, employee or otherwise) for a Competitor, including, without limitation, the ownership of any interest in, the provision of any financing, management or advisory services to, any connection with or being a
principal, partner or agent of, any Competitor; provided that the Eligible Employee may passively own less than 1% of the outstanding shares of any Competitor. 
  

 3 

 Section 2.11 “Competitor” means any one or more of the following:

 (a) any person doing business in the United States or any of its Divisions (i.e., any distinct group or unit organized as a segment
or portion of a person that is devoted to the production, provision or management of a common product or service or group of related products or services, regardless of whether the group is organized as a legally distinct entity) employing the
Eligible Employee if the person or its Division receives at least 15% of its gross U.S. operating revenues from a line of business in which the Company receives at least 3% of its gross U.S. operating revenues; 
 (b) any person doing business in the United States or any of its Divisions employing the Eligible Employee, operating for less than five years a line of
business from which the Company derives at least 3% of its gross U.S. operating revenues, notwithstanding such person’s or Division’s lack of substantial revenues in such line of business; or 
 (c) any person doing business in the United States or any of its Divisions employing the Eligible Employee if the person or its Division receives at
least 15% of its gross U.S. operating revenues from a line of business in which the Company has operated for less than five years, notwithstanding the Company’s lack of substantial revenues in such line of business. 
 For purposes of the foregoing, gross U.S. operating revenues of the Company and such other person shall be those of the Company or such person, together with their
consolidated affiliates (with whom the financial statements of such person are required, under generally accepted accounting principles, to be reported on a consolidated basis), but those of the Division then employing and the Division proposing to
employ the Eligible Employee shall each be on a stand-alone basis, all measured by the most recent available financial information of both the Company and such other person or Division at the time the Eligible Employee accepts, or proposes to accept
employment with or to otherwise perform services for such person. If financial information is not publicly available or is inadequate for purposes of applying this definition, the burden shall be on the Eligible Employee to demonstrate that such
person is not a Competitor. 
 Section 2.12 “Effective Date” means July 1, 2007. 
 Section 2.13 “Eligible Employee” means an Employee who is in the Director job tier or above. If there is any question as to
whether an Employee is deemed an Eligible Employee for purposes of the Plan, the Committee shall make the determination. 
 Section 2.14 “Employee” means an individual employed by the Employer as a common law employee, and shall not include any person working for the Employer through a temporary service or on a leased basis or who is
hired by the Employer as an independent contractor, consultant, or otherwise as a person who is not an employee, or not treated as such, for purposes of withholding federal employment taxes, as evidenced by payroll records or a written agreement
with the individual, regardless of any contrary governmental or judicial determination or holding relating to such status or tax withholding. Any change of characterization of an individual shall take effect on the actual date of such change without
regard to any retroactive recharacterization. 
 Section 2.15 “Employer” means the Company and its Subsidiaries.

  

 4 

 Section 2.16 “ERISA” means the Employee Retirement Income Security Act of
1974, as amended, and regulations thereunder. 
 Section 2.17 “Exchange Act” means the Securities Exchange Act
of 1934, as amended. 
 Section 2.18 Good Reason Resignation” means an Eligible Employee’s written resignation
within 90 days of the occurrence of any of the following circumstances that occurs within 6 months before or 12 months after the date of a Change in Control, unless such circumstances are fully corrected by the Employer within 30 days following
written notice from the Eligible Employee: 
 (a) a substantial adverse alteration in the nature or status of the Eligible Employee’s
duties from those immediately before the Change in Control or any reduction in the Eligible Employee’s job grade or tier, if applicable; 
 (b) a reduction in the Eligible Employee’s Base Salary, except for an across the board reduction similarly affecting all Eligible Employees of the Company in the affected Eligible Employee’s job tier, of more than 10% of the
Eligible Employee’s Base Salary in effect on the date of the Change in Control; 
 (c) a reduction in the Eligible Employee’s total
incentive compensation opportunity (which includes short term target incentive opportunity and long term incentive target opportunity), except for an across the board reduction similarly affecting all Eligible Employees of the Company in the
affected Eligible Employee’s job tier, of more than 20% of the Eligible Employee’s total incentive compensation opportunity in effect on the date of the Change in Control; 
 (d) relocation of the Eligible Employee’s principal place of business to a location more than 75 miles from its current location; 
 (e) the Company’s failure to provide the Eligible Employee with retirement, health, welfare and fringe benefits substantially similar in the
aggregate to those he or she enjoyed under the Company’s benefit plans in which the Eligible Employee was participating at the time of the Change in Control, unless an equitable arrangement has been made on a basis not materially less favorable
both in terms of the amount of benefits and the level of participation relative to other similarly situated executives, except for an across the board reduction similarly affecting all Eligible Employees of the Company; or 
 (f) the Company’s failure to obtain an agreement from any successor to assume and agree to continue this Plan for at least one year with respect to
Eligible Employees who were employed by the Employer at the time of a Change in Control. 
 Section 2.19 “Involuntary
Termination” means a termination of the Eligible Employee’s employment, initiated by the Employer for any reason other than Cause, Permanent Disability or death. An Eligible Employee’s refusal to accept a Non-Comparable Position
is considered an Involuntary Termination. 
 Section 2.20 “Non-CIC Termination” means an Eligible
Employee’s Involuntary Termination of employment prior to a Change in Control. 
  

 5 

 Section 2.21 “Non-Comparable Position” means a new job position offered to
an Eligible Employee that reflects either of the following circumstances: 
 (a) a reduction in the Eligible Employee’s Base Salary,
except for an across the board reduction similarly affecting all Eligible Employees of the Company in the affected Eligible Employee’s job tier, of more than 10% of the Eligible’s Employee’s Base Salary in effect immediately prior to
the new job position; 
 (b) a reduction in the Eligible Employee’s total incentive compensation opportunity (which includes short term
target incentive opportunity and long term incentive target opportunity), except for an across the board reduction similarly affecting all Eligible Employees of the Company in the affected Eligible Employee’s job tier, of more than 20% of the
Eligible Employee’s total incentive compensation opportunity in effect immediately prior to the new job position; or 
 (c) for Eligible
Employees in the Company’s director job tier at the time of the new job offer, relocation of the Eligible Employee’s principal place of business to a location more than 75 miles from its current location. 
 Section 2.22 “Non-Compete Period” means the period of time, as specified in Section 6.03(c), during which certain of
the restrictive covenants in Article VI shall be enforceable. 
 Section 2.23 “Non Executive Separation Plan”
means the Embarq Corporation Separation Plan, which plan is superseded by this Plan with respect to each Eligible Employee’s participation in such plan in the event of any Participant’s termination of employment. 
 Section 2.24 “Participant” means any Eligible Employee who meets the requirements of Article III and thereby becomes
eligible for salary continuation and other benefits under the Plan. 
 Section 2.25 “Permanent Disability” means
that an Eligible Employee has a permanent and total incapacity from engaging in any employment for the Employer for physical or mental reasons. A “Permanent Disability” shall be deemed to exist if the Eligible Employee is judged to satisfy
the requirements for disability benefits under the Company’s long-term disability plan or the requirements for disability benefits under the Social Security law then in effect. 
 Section 2.26 “Plan” means the Embarq Corporation Executive Severance Plan, as set forth herein, as the same may be amended
from time to time. 
 Section 2.27 “Plan Administrator” means one or more individuals appointed by the Committee
to administer the terms of the Plan as set forth herein and if no individual is appointed by the Committee to serve as the Plan Administrator for the Plan, the Plan Administrator shall be the Senior Vice President of Human Resources (or the
equivalent). Notwithstanding the preceding sentence, in the event the Plan Administrator is entitled to Severance Benefits under the Plan, the Committee or its delegate shall act as the Plan Administrator for purposes of administering the terms of
the Plan with respect to the Plan Administrator. The Plan Administrator may delegate all or any portion of its authority under the Plan to any other person(s). 
  

 6 

 Section 2.28 “Release” means the Separation of Employment Agreement and
General Release, substantially in the form attached hereto as Exhibit B, as the same may be amended from time to time. 
 Section 2.29 “Service” means the total number of years and completed months the Participant was an Employee of the Employer. Service with any predecessor employer or with a Subsidiary prior to the
Subsidiary’s becoming part of the Employer shall be recognized only to the extent specified in the merger or acquisition documentation. Periods of authorized leave of absence, such as military leave, will be included in Service only to the
extent required by applicable law. Any period of employment with the Company, a Subsidiary, or a predecessor employer for which an Eligible Employee previously received severance benefits, shall be excluded from Service. 
 Section 2.30 “Severance Benefit” means the salary replacement amounts and other benefits that a Participant is eligible to
receive pursuant to Article IV of the Plan. 
 Section 2.31 “Severance Period” means the period of time for
which a Participant is entitled to receive Severance Benefits pursuant to Article IV of the Plan. 
 Section 2.32
“Specified Employee” means (i) an officer of the Company or its Subsidiaries having annual compensation greater than $135,000 (adjusted for inflation as described in section 416(i) of the Code), (ii) a 5 percent owner of
the Company and its Subsidiaries, or (iii) a one percent owner of the Company and its Subsidiaries who has annual compensation from the Company and its Subsidiaries greater than $150,000, as determined by the Committee in accordance with
section 409A of the Code. The number of officers who are considered Specified Employees shall be limited to 50 employees as described in section 416(i) of the Code. The Committee shall determine the Specified Employees each year in accordance with
section 416(i) of the Code, the “specified employee” requirements of section 409A of the Code, and applicable regulations. Effective January 1, 2008, Specified Employees shall be identified as of December 31 of each year with
respect to the 12-month period beginning on the next following April 1. 
 Section 2.33 “Subsidiary”
means (i) a subsidiary of the Company (wherever incorporated), (ii) any separately organized business unit, whether or not incorporated, of the Company, and (iii) any employer that is required to be aggregated with the Company
pursuant to section 414 of the Code and regulations issued thereunder. 
 Section 2.34 “Termination Date” means
the date on which the active employment of the Eligible Employee by the Employer is severed, whether by reason of an Involuntary Termination, Voluntary Resignation, Good Reason Resignation or Termination for Cause. 
 Section 2.35 “Voluntary Resignation” means any retirement or termination of employment that is not initiated by the Employer
other than a Good Reason Resignation. 
 Section 2.36 “Year of Service” means each completed year of Service.

  

 7 

 ARTICLE III 
 PARTICIPATION AND ELIGIBILITY FOR BENEFITS 
 Section 3.01
Participation. Each Eligible Employee who incurs a CIC Termination or a Non-CIC Termination and who satisfies the conditions of Section 3.02 shall be a Participant and shall receive the Severance Benefits described in the Plan.
Participation in the Plan is expressly conditioned upon the Eligible Employee executing a Participation Agreement, substantially in the form attached hereto as Exhibit A, pursuant to which the Eligible Employee agrees to be bound by the
restrictive covenants set forth in Article VI as of the date of execution of the Participation Agreement. If an Eligible Employee is a party to an employment agreement with the Employer pursuant to which he or she is entitled to severance benefits
upon his or her termination of employment, such Eligible Employee must agree to forego the severance benefits provided under the employment agreement and affirmatively elect to participate in the Plan by executing a Participation Agreement. Upon
execution of a Participation Agreement, such Eligible Employee’s employment agreement shall be null and void. An Eligible Employee shall not be eligible to receive any other severance benefits from the Employer on account of a CIC Termination
or a Non-CIC Termination, including pursuant to the Non Executive Separation Plan, unless otherwise provided in this Plan. 
 Section 3.02 Conditions. 
 (a) Eligibility for any Severance Benefits is expressly conditioned on the Eligible
Employee’s (i) execution of a Release in connection with his or her termination of employment with the Employer; (ii) compliance with all the terms and conditions of such Release; (iii) execution of a Participation Agreement
binding the Eligible Employee to the restrictive covenants set forth in Article VI during and after the Participant’s employment with the Employer; (iv) compliance with all the terms and conditions of such Participation Agreement and the
restrictive covenants set forth in Article VI; (v) execution of a written agreement that authorizes the deduction of amounts owed to the Employer prior to the payment of any Severance Benefit (or in accordance with any other schedule as the
Plan Administrator may determine to be appropriate); and (vi) acknowledgement that all decisions and determinations of the Board, the Committee and the Plan Administrator shall be final and binding on the Eligible Employee, his or her
beneficiaries and any other person having or claiming an interest under the Plan on his or her behalf. 
 (b) If the Plan Administrator
determines that the Participant has not fully complied with any of the terms of the Plan, the Participation Agreement and/or the Release, the Plan Administrator, acting on behalf of the Company, may deny Severance Benefits not yet in pay status or
discontinue the payment of the Participant’s Severance Benefits and may require the Participant to repay any portion of any Severance Benefits already received under the Plan, by providing written notice of such repayment obligation to the
Participant. If the Plan Administrator notifies a Participant that repayment of all or any portion of the Severance Benefit received under the Plan is required, such amounts shall be repaid within 30 calendar days of the date the written notice is
sent. Any remedy under this subsection (b) shall be in addition to, and not in place of, any other remedy, including injunctive relief, that the Company may have. 
  

 8 

 ARTICLE IV 
 DETERMINATION OF SEVERANCE BENEFITS 
 Section 4.01 Non-CIC Termination. The
Severance Benefits to be provided to a Participant who incurs a Non-CIC Termination and becomes a Participant shall be as follows: 
 (a)
Base Salary. The Participant shall receive his or her Base Salary for the Severance Period applicable to the Participant as follows: 
 (i) If the Participant is a Director, he or she shall be entitled to receive 6 weeks of Base Salary plus an additional 2 weeks of Base Salary for each Year of Service up to a maximum of 52 weeks. 
 (ii) If the Participant is a Vice President, he or she shall be entitled to receive 12 weeks of Base Salary plus an additional 2 weeks of Base Salary
for each Year of Service up to a maximum of 52 weeks. 
 (iii) If the Participant is a Senior Vice President or above, he or she shall be
entitled to receive 52 weeks of Base Salary. 
 (b) Short-Term Incentive Payment . The Participant shall receive an additional, single
lump sum payment based on his target opportunity under the Short-Term Incentive Program equal to 80% of the Participant’s target opportunity for the fiscal year in which the Termination Date occurs, prorated based on the length of the Severance
Period. 
 (c) Continued Employee Benefits. All Participants shall continue to be eligible to participate in the Company’s
Flexible Benefit Program (or successor thereto, but excluding participation in the supplemental long-term disability plan) and the Employee Assistance Program (or generally comparable coverage) for himself or herself and, where applicable, his or
her eligible dependents, as the same may be changed from time to time for employees of the Employer generally, as if the Participant had continued in employment during the Severance Period. In accordance with the provisions of the Company’s
Short-Term Disability Plan and the Company’s Basic Long-Term Disability Plan, a Participant shall not be eligible to participate in or receive benefits from these plans during the Severance Period. The Participant shall be responsible for the
payment of the employee portion of the contributions that are required during the Severance Period and such contributions shall be made within the time period and in the amounts that Employees are required to pay to the Employer for similar
coverage. The Participant’s failure to pay the applicable contributions shall result in the cessation of the applicable coverage for the Participant and his or her eligible dependents. Notwithstanding any other provision of the Plan to the
contrary, in the event that a Participant commences employment with another company at any time during the Severance Period, the Participant will cease receiving coverage under the Employer’s benefit plans if eligible for coverage under the
other company’s benefit plans. Within 30 days of a Participant’s commencement of employment with another company, the Participant shall provide the Company written notice of such employment and provide information to the Company regarding
the benefits provided to the Participant by his or her new employer. The COBRA continuation coverage period under section 4980B of the Code shall begin coincident with the first day of the month following the Severance Period, or the first day of
the month following the commencement of coverage with another company, whichever occurs first. 
  

 9 

 (d) Retirement Plans. The provisions of the Embarq Retirement Pension Plan and the Embarq
Retirement Savings Plan, any successor plans thereto or any other retirement plans maintained by the Company pursuant to which a Participant is eligible to participate, shall control with respect to the recognition of service during the Severance
Period and the eligibility for benefits following the Severance Period. 
 (e) Equity. The provisions of the Embarq Corporation 2006
Equity Incentive Plan, any successor plan thereto or any other equity compensation plan maintained by the Company pursuant to which a Participant has received an equity grant, and the Participant’s relevant grant agreement shall control with
respect to the treatment of the Participant’s equity grants upon the Participant’s Non-CIC Termination. 
 (f) Outplacement
Services. The Company will pay the cost of outplacement services for the Participant at the outplacement agency designated by the Company and in accordance with the Company’s procedures regarding outplacement services unless the Company
provides prior approval for the Participant to use another outplacement agency. 
 Section 4.02 CIC Termination. The
Severance Benefits to be provided to a Participant who incurs a CIC Termination and becomes a Participant shall be as follows: 
 (a) Base
Salary. The Participant shall receive his or her Base Salary for the Severance Period applicable to the Participant as follows: 
 (i)
If the Participant is a Director, he or she shall be entitled to receive 6 weeks of Base Salary plus an additional 2 weeks of Base Salary for each Year of Service up to a maximum of 52 weeks, but in no event less than 39 weeks. 
 (ii) If the Participant is a Vice President, he or she shall be entitled to receive 52 weeks of Base Salary. 
 (iii) If the Participant is a Senior Vice President, he or she shall be entitled to receive 78 weeks of Base Salary. 
 (iv) If the Participant is the Chief Executive Officer, Chief Financial Officer, General Counsel or a Consumer and Business Unit President, he or she
shall be entitled to receive 104 weeks of Base Salary. 
 (b) Short-Term Incentive Payment . The Participant shall receive an
additional, single lump sum payment based on his target opportunity under the Short-Term Incentive Program equal to 80% of the Participant’s target opportunity for the fiscal year in which the Termination Date occurs, prorated based on the
length of the Severance Period. 
 (c) Continued Employee Benefits. All Participants shall continue to be eligible to participate in
the Company’s Flexible Benefit Program (or successor thereto, but excluding participation in the supplemental long-term disability plan) and the Employee Assistance Program (or generally comparable coverage) for himself or herself and, where
applicable, his or her eligible dependents, 

  

 10 

 
as the same may be changed from time to time for employees of the Employer generally, as if the Participant had continued in employment during the Severance
Period. In accordance with the provisions of the Company’s Short-Term Disability Plan and the Company’s Basic Long-Term Disability Plan, a Participant shall not be eligible to participate in or receive benefits from these plans during the
Severance Period. The Participant shall be responsible for the payment of the employee portion of the contributions that are required during the Severance Period and such contributions shall be made within the time period and in the amounts that
Employees are required to pay to the Employer for similar coverage. The Participant’s failure to pay the applicable contributions shall result in the cessation of the applicable coverage for the Participant and his or her eligible dependents.
In the event that a Participant’s Severance Period is longer than 18 months, beginning with the first day of the nineteenth month, the Participant will no longer be eligible to participate in the Flexible Benefit Program and the Company shall
provide such Participant with an after-tax amount sufficient to cover the employer-paid portion of the cost of the continued medical, dental and vision coverage on the twelfth business day of each month beginning with the nineteenth month of the
Severance Period and ending with the last month of the Severance Period. Notwithstanding any other provision of the Plan to the contrary, in the event that a Participant commences employment with another company at any time during the Severance
Period, the Participant will cease receiving coverage under the Employer’s benefit plans if eligible for coverage under the other company’s benefit plans. Within 30 days of a Participant’s commencement of employment with another
company, the Participant shall provide the Company written notice of such employment and provide information to the Company regarding the benefits provided to the Participant by his or her new employer. The COBRA continuation coverage period under
section 4980B of the Code shall begin coincident with (i) the first day of the month following the Severance Period, (ii)the first day of the month following the commencement of coverage with another company, or (iii) in the event the
Participant’s Severance Period is longer than 18 months, the first day of the nineteenth month, whichever occurs first. 
 (d)
Retirement Plans. The provisions of the Embarq Retirement Pension Plan and the Embarq Retirement Savings Plan, any successor plans thereto or any other retirement plans maintained by the Company pursuant to which a Participant is eligible to
participate, shall control with respect to the recognition of service during the Severance Period and the eligibility for benefits following the Severance Period. 
 (e) Equity. The provisions of the Embarq Corporation 2006 Equity Incentive Plan, any successor plan thereto or any other equity compensation plan maintained by the Company pursuant to which a Participant has
received an equity grant, and the Participant’s relevant grant agreement shall control with respect to the treatment of the Participant’s equity grants upon the Participant’s CIC Termination. 
 (f) Outplacement Services. The Company will pay the cost of outplacement services for the Participant at the outplacement agency designated by the
Company and in accordance with the Company’s procedures regarding outplacement services unless the Company provides prior approval for the Participant to use another outplacement agency. 
 Section 4.03 Voluntary Resignation; Termination for Death or Permanent Disability. If the Eligible Employee’s employment
terminates on account of the Eligible Employee’s (i) Voluntary Resignation, (ii) death, or (iii) Permanent Disability, 

  

 11 

 
then the Eligible Employee shall not be entitled to receive Severance Benefits under this Plan and shall be entitled only to those benefits (if any) as may
be available under the Employer’s then-existing benefit plans and policies at the time of such termination. 
 Section 4.04
Termination for Cause. If any Eligible Employee’s employment terminates on account of termination by the Employer for Cause, the Eligible Employee shall not be entitled to receive Severance Benefits under this Plan. Notwithstanding
any other provision of the Plan to the contrary, if the Committee determines that a Participant engaged in conduct that constitutes Cause at any time prior to the Participant’s Termination Date, any Severance Benefits payable to the Participant
under Section 4.01 or 4.02 of the Plan shall immediately cease, and the Participant shall be required to return any Severance Benefits paid to the Participant prior to such determination. The Employer may withhold paying Severance Benefits
under the Plan pending resolution of an inquiry that could lead to a determination that Cause exists. 
 Section 4.05 Approved
Military Leave. An Eligible Employee returning from approved military leave within one year after a Change in Control will be eligible for Severance Benefits if: (a) he or she is eligible for reemployment under the provisions of the
Uniformed Services Employment and Reemployment Rights Act (USERRA); (b) his or her pre-military leave job is eliminated; and (c) the Employer’s circumstances are changed so as to make reemployment in another position impossible or
unreasonable, or re-employment would create an undue hardship for the Employer. If the Eligible Employee qualifies for Severance Benefits under this Section 4.05, his or her severance benefits will be calculated as if the Eligible Employee had
remained continuously employed from the date he or she began his or her military leave. The Eligible Employee must also satisfy any other relevant conditions for payment, including execution of a Release. 
 Section 4.06 Reduction of Severance Benefits. The Plan Administrator reserves the right to make deductions in accordance with
applicable law for any monies owed to the Employer by the Participant or the value of Employer property that the Participant has retained in his or her possession. 
 ARTICLE V 
 METHOD OF PAYMENT AND LIMITATION ON BENEFITS 
 Section 5.01 Method of Payment. The cash Severance Benefits payable under Sections 4.01 or 4.02 above, as applicable, attributable to
(a) a Participant’s Base Salary, shall be paid pursuant to the Company’s normal payroll practices, and (b) the Short-Term Incentive payment payable under Section 4.01(b) or 4.02(b), shall be paid at the time of the last Base
Salary payment pursuant to subsection (a) above; provided however, that no payment shall be made prior to the Participant’s execution of the Release required under Section 3.02, and the expiration of any revocation period, if
applicable, specified in the Release. In no event will interest be credited on the unpaid balance for which a Participant may become eligible. Payment shall be made by direct deposit or by mailing to the last address provided by the
Participant to the Employer or such other reasonable method as determined by the Plan Administrator. All payments of Severance Benefits are subject to applicable federal, state and local taxes and withholdings. 
  

 12 

 
In the event of the Participant’s death after he or she becomes eligible for Severance Benefits under the Plan, but prior to full payment of all
Severance Benefits due to such Participant, any remaining Severance Benefits due to the Participant shall be paid to the Participant’s estate in a lump sum payment within 60 days following written notification of the Participant’s death.

 Section 5.02 409A Delay. Notwithstanding Section 5.01 above, any amounts payable to a Specified Employee that are
deferred compensation under section 409A of the Code that are not excluded from section 409A under the separation pay exception or the short-term deferral exception shall be paid no sooner than the first day of the seventh month following a
Specified Employee’s CIC Termination. This provision shall not be construed as preventing an amount of Severance Benefits up to 2 times the lesser of (a) the Specified Employee’s annualized compensation for the year prior to the year
of termination or resignation, as applicable, and (b) the maximum amount that may be taken into account under a qualified plan pursuant to section 401(a)(17) of the Code, being paid to a Specified Employee in the first 6 months following his or
her termination or resignation, as applicable. 
 Section 5.03 Limitation on Benefits. 
 (a) Notwithstanding anything set forth in the Plan to the contrary, if any payment or benefit, including the Severance Benefits, a Participant would
receive from the Employer pursuant to a Change in Control or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of section 280G of the Code and (ii) but for this sentence, be
subject to the excise tax imposed by section 4999 of the Code (the “Excise Tax”), then such Payment shall be reduced to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the
Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in the Participant’s receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some
portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits (or a cancellation of the acceleration of vesting of stock options or equity awards) constituting “parachute payments” is necessary so that the
Payment equals the Reduced Amount, such reduction and/or cancellation of acceleration shall occur in the order that provides the maximum economic benefit to the Participant. In the event that acceleration of vesting of a stock option or equity award
is to be reduced, such acceleration of vesting also shall be canceled in the order that provides the maximum economic benefit to the Participant. 
 (b) The Company shall appoint a nationally recognized accounting firm with appropriate subject matter expertise to make the determinations required under this Section 5.02. 
 (c) The Company shall bear all expenses with respect to the making of the determinations by such accounting firm required to be made under this
Section 5.02. The accounting firm engaged to make the determinations under this Section 5.02 shall provide its calculations, together with detailed supporting documentation, to the Company and the Participant as soon as practicable after
the date on which the Participant’s right to a Payment is triggered (if requested at that time by the Company or the Participant) or such other time as requested by the Company or the Participant. If the accounting firm determines that no
Excise Tax is payable with respect 

  

 13 

 
to a Payment, either before or after the application of the Reduced Amount, it shall furnish the Company with an opinion reasonably acceptable to the
Participant that no Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the accounting firm made under this Section 5.02 shall be final, binding, and conclusive upon the Company and the Participant.

 ARTICLE VI 
 RESTRICTIVE COVENANTS 
 Section 6.01 Principles of Business Conduct. Each Eligible Employee shall
adhere in all respects to the Employer’s Principles of Business Conduct (or any successor code of conduct) as they may from time to time be established, interpreted, amended or terminated. 
 Section 6.02 Proprietary Information. 
 (a) Each Eligible Employee shall acknowledge that, during the course of his or her employment, the Eligible Employee has learned or will learn or develop Proprietary Information. Each Eligible Employee shall further
acknowledge that unauthorized disclosure or use of such Proprietary Information, other than in discharge of the Eligible Employee’s duties, will cause the Employer irreparable harm. Except in the course of his or her employment with the
Employer, in pursuit of the business of the Employer, or as otherwise required in employment with the Employer or by applicable law, each Eligible Employee shall not, during the course of his or her employment or at any time following termination of
his or her employment, directly or indirectly, disclose, publish, communicate, or use on his or her behalf or another’s behalf, any Proprietary Information. If during or after his or her employment, the Eligible Employee has any questions about
whether particular information is Proprietary Information, the Eligible Employee shall consult with the Company’s General Counsel or other representative designated by the Company. 
 (b) Each Eligible Employee shall also agree to promptly disclose to the Employer any information, ideas, or inventions made or conceived by him or her
that results from or are suggested by services performed by the Eligible Employee for the Employer, and to assign to the Employer all rights pertaining to such information, ideas, or inventions. Knowledge or information of any kind disclosed by the
Eligible Employee to the Employer shall be deemed to have been disclosed without obligation on the part of the Employer to hold the same in confidence, and the Employer shall have the full right to use and disclose such knowledge and information
without compensation to the Eligible Employee. 
 Section 6.03 Non-Competition. 
 (a) During the Eligible Employee’s employment with the Employer and during the Non-Compete Period, each Eligible Employee shall agree that he or she
shall not engage in Competitive Employment. 
 (b) If an Eligible Employee ceases to be employed by the Employer because of the sale,
spin-off, divestiture, or other disposition by the Company of a Subsidiary, division, or other divested unit employing the Eligible Employee, this provision shall 

  

 14 

 
continue to apply during the Non-Compete Period, except that the Eligible Employee’s continued employment for the Subsidiary, division, or other
divested unit disposed of by the Company shall not be deemed a violation of this provision. 
 (c) A Participant’s Non-Compete Period
shall equal his or her Severance Period as determined under Section 4.01 or 4.02 above, as applicable. 
 Section 6.04
Inducement of Employees, Customers and Others. During an Eligible Employee’s employment with the Employer and during the Non-Compete Period, each Eligible Employee shall agree that he or she will not, directly or indirectly, solicit,
induce, or encourage any employee, consultant, agent or customer of the Company or its Subsidiaries or vendors or other parties doing business with the Company or its Subsidiaries, to terminate their employment, agency, or other relationship with
the Company or its Subsidiaries or to render services for or transfer business to any Competitor, and each Eligible Employee shall not initiate discussion with any such person for any such purpose or authorize or knowingly cooperate with the taking
of any such actions by any other individual or entity on behalf of the Competitor. 
 Section 6.05 No Adverse Actions.
During the Non-Compete Period, each Eligible Employee shall not, without the prior written consent of the Company, in any manner, solicit, request, advise, or assist any other person to (a) undertake any action that would be reasonably likely
to, or is intended to, result in a Change in Control, or (b) seek to control the Board, in any material manner. 
 Section 6.06
Return of Property. Each Eligible Employee shall, upon the Eligible Employee’s Termination Date, return to the Employer all property of the Employer in the Eligible Employee’s possession, including all notes, reports, sketches,
plans, published memoranda, or other documents, whether in hard copy or in electronic form, created, developed, generated, received, or held by the Eligible Employee during the Eligible Employee’s employment, concerning or related to the
Employer’s business, whether or not containing or relating to Proprietary Information. Each Eligible Employee shall not remove, by e-mail, by removal of computer discs or hard drives, or by other means, any of the above property containing
Proprietary Information, or reproductions or copies thereof, or any apparatus from the Employer’s premises without the Employer’s written consent. 
 Section 6.07 Non-Disparagement. Each Eligible Employee shall agree to refrain from making any statements about the Company, its Subsidiaries or their officers or directors that would disparage, or
reflect unfavorably upon the image or reputation of the Company, its Subsidiaries or any such officer or director. 
 Section 6.08
Assistance with Claims. 
 (a) Each Eligible Employee shall agree, that, during and after the Eligible Employee’s employment
by the Employer, the Eligible Employee shall assist the Company, on a reasonable basis, in the defense of any claims or potential claims that may be made or threatened to be made against it in any action, suit, or proceeding, whether civil,
criminal, administrative, or investigative (“Proceeding”) and shall assist the Company in the prosecution of any claims that may be made by the Company in any Proceeding, to the extent that such claims may relate to the Eligible
Employee’s services. 
  

 15 

 (b) Each Eligible Employee shall agree, unless precluded by law, to promptly inform the Company if the
Eligible Employee is asked to participate (or otherwise become involved) in any Proceeding involving such claims or potential claims. 
 (c)
Each Eligible Employee shall also agree, unless precluded by law, to promptly inform the Company if the Eligible Employee is asked to assist in any investigation (whether governmental or private) of the Company or its Subsidiaries (or its actions),
regardless of whether a lawsuit has then been filed against the Company or its Subsidiaries with respect to such investigation. 
 (d) The
Company agrees to reimburse an Eligible Employee for all of the Eligible Employee’s reasonable out-of-pocket expenses associated with such assistance, including travel expenses and any attorneys’ fees and shall pay a reasonable per diem
fee (equal to 1/250th of the Eligible Employee’s Base Salary rate at the Eligible Employee’s Termination Date) for the Eligible Employee’s services. 
 Section 6.09 Reasonableness. In the event that any of the provisions of this Article VI should ever be adjudicated to exceed the time, geographic, service, or other limitations permitted by
applicable law in any jurisdiction, then such provisions shall be deemed reformed in such jurisdiction to the maximum time, geographic, service, or other limitations permitted by applicable law. 
 Section 6.10 Equitable Relief. 
 (a) Each Eligible Employee shall acknowledge that the restrictions contained in this Article VI are reasonable and necessary to protect the legitimate interests of the Company, its Subsidiaries and its affiliates, that the Company would not
have established this Plan in the absence of such restrictions, and that any violation of any provision of this Article VI will result in irreparable injury to the Company. Each Eligible Employee shall represent that his or her experience and
capabilities are such that the restrictions contained in this Article VI will not prevent the Eligible Employee from obtaining employment or otherwise earning a living at the same general level of economic benefit as is currently the case. Each
Eligible Employee shall further represent and acknowledge that (i) he or she has been advised by the Company to consult his or her own legal counsel in respect of this Plan, and (ii) that he or she has had full opportunity, prior to
agreeing to participate in this Plan, to review thoroughly this Plan with his or her counsel. 
 (b) Each Eligible Employee shall agree that
the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving actual damages and without posting a bond or other security, as well as an equitable accounting of all earnings, profits and other
benefits arising from any violation of this Article VI, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled. 
  

 16 

 (c) Each Eligible Employee shall irrevocably and unconditionally (i) agree that any suit, action or
other legal proceeding arising out of this Article VI, including without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, must be brought, as appropriate, in the Kansas
District Court located in Johnson County, Kansas, or in the United States District Court for the District of Kansas in Kansas City, Kansas, (ii) consent to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding,
and (iii) waive any objection which the Eligible Employee may have to the laying of venue of any such suit, action or proceeding in any such court. Each Eligible Employee shall also irrevocably and unconditionally consent to the service of any
process, pleadings, notices or other papers in a manner permitted by the notice provisions of Section 10.04. 
 Section 6.11
Survival of Provisions. The obligations contained in this Article VI shall survive the termination of each Eligible Employee’s employment with the Employer and shall be fully enforceable thereafter. 
 ARTICLE VII 
 COMMITTEE; PLAN
ADMINISTRATOR 
 Section 7.01 Authority and Duties. Except with respect to such duties as are specifically
allocated to the Committee under the Plan, it shall be the duty of the Plan Administrator, on the basis of information supplied to the Plan Administrator by the Company and the Committee, to properly administer the Plan. The Plan Administrator shall
have the full power, authority and discretion to construe, interpret and administer the Plan, to make factual determinations, to correct deficiencies therein, and to supply omissions. The Plan Administrator may adopt such rules and regulations and
may make such decisions as it deems necessary or desirable for the proper administration of the Plan. 
 Section 7.02 Compensation
of the Plan Administrator and the Committee. The Plan Administrator and the Committee shall receive no compensation for services as such. However, all reasonable expenses of the Plan Administrator and the Committee shall be paid or
reimbursed by the Company upon proper documentation. The Plan Administrator and the Committee shall be indemnified by the Company against personal liability for actions taken in good faith in the discharge of the Plan Administrator’s or the
Committee’s duties, as applicable. 
 Section 7.03 Records, Reporting and Disclosure. The Plan Administrator shall
keep a copy of all records relating to the payment of Severance Benefits to Participants and former Participants and all other records necessary for the proper operation of the Plan. All Plan records shall be made available to the Committee, the
Company and to each Participant for examination during business hours except that a Participant shall examine only such records as pertain exclusively to the examining Participant and to the Plan. The Plan Administrator shall prepare and shall file
as required by law or regulation all reports, forms, documents and other items required by ERISA, the Code, and every other relevant statute, each as amended, and all regulations thereunder (except that the Employer, as payor of the Severance
Benefits, shall prepare and distribute to the proper recipients all forms relating to withholding of income or wage taxes, Social Security taxes, and other amounts that may be similarly reportable). 
  

 17 

 Section 7.04 Discretion. Any decisions, actions or interpretations to be made under
the Plan by the Board, the Committee, or the Plan Administrator (acting on its own behalf or on behalf of the Board or the Committee) shall be made in each of their respective sole and absolute discretion, not in any fiduciary capacity (except with
respect to the Plan Administrator acting on its own behalf) and need not be uniformly applied to similarly situated individuals and such decisions, actions or interpretations shall be final, binding and conclusive upon all parties, subject only to
determinations by the Named Appeals Fiduciary (as defined in Section 9.04), with respect to denied claims for Severance Benefits. 
 ARTICLE VIII 
 AMENDMENT, SUSPENSION AND TERMINATION 
 Section 8.01 Amendment, Suspension and Termination. 
 (a) In General. Except as otherwise provided in this Article VIII, the Board or its delegate shall have the right, at any time and
from time to time, to amend, suspend or terminate the Plan in whole or in part, for any reason or without reason, and without either the consent of or the prior notification to any Participant or Eligible Employee. In the event of any amendment,
suspension or termination that has a material adverse effect on an Eligible Employee’s benefits and/or rights under the Plan and that occurs more than 12 months before or more than 12 months after the occurrence of a Change in Control, the
Non-Compete Period applicable to that Eligible Employee will apply only for the period of time for which Severance Benefits under the Plan are actually payable. 
 (b) In Event of a Change in Control. Any amendment, suspension or termination that adversely affects an Eligible Employee’s
benefits and/or rights under the Plan shall not apply to an Eligible Employee covered under the Plan at the time of a Change in Control if the amendment, suspension or termination is made within 12 months before or after such Change in Control
without the Eligible Employee’s written consent (and before all payments and benefits hereunder associated with such Change in Control are paid), except as may be otherwise required to comply with changes in applicable laws or regulations,
including as set forth in Section 10.13. 
 (c) No Recovery of Benefits. No amendment, suspension or termination
shall give the Company the right to recover any amount paid to a Participant prior to the date of the amendment, suspension or termination (except as provided in Section 3.02(b)) or to cause the cessation of Severance Benefits after a
Participant has executed a Release as required under Section 3.02. 
 Section 8.02 Continuation of Plan following a Change in
Control. Notwithstanding Section 8.01(a) but subject to Section 8.01(b), upon the occurrence of a Change in Control, the Plan shall continue until the applicable Employer has fully performed all of such Employer’s obligations
under the Plan with respect to all Participants and Eligible Employees covered under the Plan at the time of the Change in Control, and shall have paid in full all Severance Benefits under the Plan associated with such Change in Control. 

 

 18 

 ARTICLE IX 
 CLAIMS PROCEDURES 
 Section 9.01 Claims. A Participant or his or her
beneficiary, as applicable (the “claimant”) may contest only the administration of the Severance Benefits awarded by completing and filing with the Plan Administrator a written request for review in the manner specified by the Plan
Administrator within 90 days following the Participant’s termination of employment. Each such application must be supported by such information as the Plan Administrator deems relevant and appropriate. No appeal is permissible as to a
Participant’s eligibility for or amount of the Severance Benefit, which are decisions made within the discretion of the Company, and the Committee and the Plan Administrator acting on behalf of the Company. The claimant may not bring an action
for any alleged wrongful denial of Plan benefits in a court of law unless the claims procedures described in this Article IX are exhausted and a final determination is made by the Plan Administrator and/or the Named Appeals Fiduciary. If the
claimant challenges a decision by the Plan Administrator and/or Named Appeals Fiduciary, a review by the court of law will be limited to the facts, evidence and issues presented to the Plan Administrator during the claims procedure set forth in this
Article IX. Facts and evidence that become known to the claimant after such individual has exhausted the claims procedure must be brought to the attention of the Plan Administrator and/or Named Appeals Fiduciary for reconsideration. Issues not
raised with the Plan Administrator and/or Named Appeals Fiduciary will be deemed waived. 
 Section 9.02 Initial Claim. In
the event that any claim relating to the administration of Severance Benefits is denied in whole or in part, the claimant whose claim has been so denied shall be notified of such denial in writing by the Plan Administrator within 90 days after the
receipt of the claim for benefits. This period may be extended an additional 90 days if the Plan Administrator determines such extension is necessary and the Plan Administrator provides notice of the extension to the claimant prior to the end of the
initial 90-day period. The notice advising of the denial shall: (i) specify the reason or reasons for denial, (ii) make specific reference to the Plan provisions on which the determination was based, (iii) describe any additional
material or information necessary for the claimant to perfect the claim (explaining why such material or information is needed), and (iv) describe the Plan’s review procedures and the time limits applicable to such procedures, including a
statement of the claimant’s right to bring a civil action under section 502(a) of ERISA following an adverse benefit determination on review. 
 Section 9.03 Appeals of Denied Administrative Claims. All appeals shall be made by the following procedure: 
 (a)
A claimant whose claim has been denied shall file with the Plan Administrator a notice of appeal of the denial. Such notice shall be filed within 60 calendar days of notification by the Plan Administrator of the denial of a claim, shall be made in
writing, and shall set forth all of the facts upon which the appeal is based. Appeals not timely filed shall be barred. 
 (b) The Named
Appeals Fiduciary shall consider the merits of the claimant’s written presentations, the merits of any facts or evidence in support of the denial of benefits, and such other facts and circumstances as the Named Appeals Fiduciary shall deem
relevant. 
  

 19 

 (c) The Named Appeals Fiduciary shall render a determination upon the appealed claim which determination
shall be accompanied by a written statement as to the reasons therefor. The determination shall be made to the claimant within 60 days of the claimant’s request for review, unless the Named Appeals Fiduciary determines that special
circumstances require an extension of time for processing the claim. In such case, the Named Appeals Fiduciary shall notify the claimant of the need for an extension of time to render its decision prior to the end of the initial 60-day period, and
the Named Appeals Fiduciary shall have an additional 60-day period to make its determination. The determination so rendered shall be binding upon all parties. If the determination is adverse to the claimant, the notice shall: (i) provide the
reason or reasons for denial, (ii) make specific reference to the Plan provisions on which the determination was based, (iii) state that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies
of, all documents, records and other information relevant to a the claimant’s claim for benefits, and (iv) state that the claimant has the right to bring an action under section 502(a) of ERISA. 
 Section 9.04 Appointment of the Named Appeals Fiduciary. The Named Appeals Fiduciary shall be the person or persons named as such by
the Committee, or, if no such person or persons is so named, then the person or persons named by the Plan Administrator as the Named Appeals Fiduciary. Named Appeals Fiduciaries may at any time be removed by the Committee, and any Named Appeals
Fiduciary named by the Plan Administrator may be removed by the Plan Administrator. All such removals may be with or without cause and shall be effective on the date stated in the notice of removal. The Named Appeals Fiduciary shall be a “Named
Fiduciary” within the meaning of ERISA, and unless appointed to other fiduciary responsibilities, shall have no authority, responsibility, or liability with respect to any matter other than the proper discharge of the functions of the Named
Appeals Fiduciary as set forth herein. 
 ARTICLE X 
 MISCELLANEOUS 
 Section 10.01 Waiver of Jury Trial. 
 (a) The Employer waives and each Eligible Employee upon becoming a Participant in the Plan shall waive his, her or its right to a jury trial in any court
action arising under the Plan or otherwise and whether made by claim, counter-claim, third-party claim or otherwise. 
 (b) If for any reason
the jury waiver is held to be unenforceable, but only in that event, the Participant and the Employer agree to binding arbitration for any dispute arising out of this Plan or any claim arising under any federal, state or local statutes, laws or
regulations, pursuant to the arbitration terms set forth on attached Exhibit C. 
 (c) The agreement of the Participant to waive his
or her right to a jury trial will be binding on his or her beneficiaries or assigns and will survive the termination of this Plan. 
  

 20 

 Section 10.02 Forum Selection. Any court proceeding brought by a Participant or the
Employer must be brought, as appropriate, in Kansas District Court located in Johnson County, Kansas, or in the United States District Court for the District of Kansas in Kansas City, Kansas. Each party agrees to personal jurisdiction in either
court. 
 Section 10.03 Nonalienation of Benefits. None of the payments, benefits or rights of any Participant shall be
subject to any claim of any creditor of any Participant, and, in particular, to the fullest extent permitted by law, all such payments, benefits and rights shall be free from attachment, garnishment (if permitted under applicable law),
trustee’s process, or any other legal or equitable process available to any creditor of such Participant. No Participant shall have the right to alienate, anticipate, commute, plead, encumber or assign any of the benefits or payments that he
may expect to receive, continently or otherwise, under this Plan, except for the designation of a beneficiary. 
 Section 10.04
Notices. All notices and other communications required hereunder shall be in writing and shall be delivered personally or mailed by registered or certified mail, return receipt requested, or by overnight express courier service. In the
case of the Participant, mailed notices shall be addressed to him or her at the home address which he or she most recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to the Plan
Administrator. 
 Section 10.05 No Mitigation. Participants shall not be required to mitigate the amount of any Severance
Benefit provided for in this Plan by seeking other employment or otherwise, nor shall the amount of any Severance Benefit provided for herein be reduced by any compensation earned by other employment or otherwise, except if the Participant is
re-employed by the Employer, in which case Severance Benefits shall cease. 
 Section 10.06 No Contract of Employment.
Neither the establishment of the Plan, nor any modification thereof, nor the creation of any fund, trust or account, nor the payment of any benefits shall be construed as giving any Eligible Employee or any person whosoever, the right to be retained
in the service of the Employer, and all Eligible Employees shall remain subject to discharge to the same extent as if the Plan had never been adopted. 
 Section 10.07 Severability of Provisions. Except to the extent provided in Section 6.09, if any provision of this Plan shall be held invalid or unenforceable by a court of competent
jurisdiction, such invalidity or unenforceability shall not affect any other provisions hereof, and this Plan shall be construed and enforced as if such provisions had not been included. 
 Section 10.08 Headings and Captions. The headings and captions herein are provided for reference and convenience only, shall not be
considered part of the Plan, and shall not be employed in the construction of the Plan. 
 Section 10.09 Gender and
Number. Where the context admits: words in any gender shall include any other gender, and, except where otherwise clearly indicated by context, the singular shall include the plural, and vice-versa. 
 Section 10.10 Unfunded Plan. The Plan shall not be funded. No Participant shall have any right to, or interest in, any assets of the
Employer that may be applied by the Employer to the payment of Severance Benefits. Payments of Severance Benefits under the Plan shall be paid from the Employer’s general assets, in accordance with the terms of the Plan. 
  

 21 

 Section 10.11 Payments to Incompetent Persons. Any benefit payable to or for the
benefit of a minor, an incompetent person or other person incapable of receipting therefor shall be deemed paid when paid to such person’s guardian or to the party providing or reasonably appearing to provide for the care of such person, and
such payment shall fully discharge the Employer, the Committee and all other parties with respect thereto. 
 Section 10.12 Lost
Payees. A benefit shall be deemed forfeited if the Committee is unable to locate a Participant to whom a Severance Benefit is due. Such Severance Benefit shall be reinstated if application is made by the Participant for the forfeited
Severance Benefit while this Plan is in operation. 
 Section 10.13 Code Section 409A Compliance. To the extent
applicable, this Plan shall comply with section 409A of the Code and the regulations promulgated thereunder. If any amount paid under this Plan is determined to be “deferred compensation” within the meaning of section 409A of the Code and
compliance with one or more of the provisions of this Plan causes or results in a violation of section 409A of the Code, then such provision shall be interpreted or reformed in the manner necessary to achieve compliance with section 409A of the
Code. 
 Section 10.14 Controlling Law. This Plan shall be construed and enforced according to the laws of the State of
Kansas to the extent not superseded by Federal law. 
  

 22 

 EXHIBIT A 
 Participation Agreement 
 THIS PARTICIPATION AGREEMENT (this “Agreement”) is made
and entered into as of                     ,     , 2007 by and between
                                 (the “Employee”) and Embarq
Corporation, a Delaware corporation (the “Company”), on behalf of itself and its subsidiary which employs the Employee. 
 The Employee is eligible to participate in the Embarq Corporation Executive Severance Plan (the “Plan”). The Employee accepts participation in the Plan and, intending to be legally bound, agrees as follows: 
 1. Participation in the Plan; Termination of any other Rights to Severance Benefits. Pursuant to the terms of the Plan, I agree to forego any other
benefits or payments to which I may otherwise be entitled under the terms of any other plan, program or agreement of the Company which provides for the payment of severance benefits in the event of my termination of employment whether in connection
with a change in control of the Company or otherwise[, including any rights I may have under my employment agreement with the Company, dated
                                 (the “Employment Agreement”). I
understand and agree that by executing this Agreement, the Employment Agreement shall be null and void and of no further effect as of the date hereof]. 
 2. Employee’s Undertakings. I agree to be bound by all of the restrictive covenants set forth in Article VI of the Plan and accept the reasonableness of the equitable relief provisions set forth in
Sections 6.09 and 6.10 of the Plan. 
 This Agreement has been duly executed as of the day and year first written above. 
  

							
		 	 EMBARQ CORPORATION
	 		 	
				
	 By:
	 	  
	 	Title:	 	  

 I hereby acknowledge that I have had the opportunity to review and consider the Plan and the restrictive covenants
set forth in Article VI of the Plan. I hereby accept my right to receive potential Severance Benefits described in this Agreement and the Plan and agree to be bound by the terms of the Plan and this Agreement including the restrictive covenants set
forth in Article VI of the Plan. I hereby further agree that all the decisions and determinations of the Committee and/or Plan Administrator, as applicable, shall be final and binding. 
  

	
	  

	 Employee

  

 A 

 EXHIBIT B 
 Form of Release Agreement 
 [NOTE: The terms and conditions of this Form of Release Agreement may be modified by
the Company at the advice of counsel to satisfy applicable legal requirements.] 
  

			
	Employee Name:	 	  

	Work City, State:	 	Overland Park, Kansas

 Notice to Employee: You should discuss this General Release Agreement with an attorney prior to signing it but,
in any event, you should thoroughly review and understand the effect of this document before acting upon it. Therefore, please take this General Release Agreement home and carefully consider it before you decide whether to sign it. You have up to 45
calendar days from the date of receipt of this General Release Agreement in which to decide whether to sign it. 
 GENERAL RELEASE AGREEMENT

 THIS GENERAL RELEASE AGREEMENT is entered into this          day of
                    , 200    , by and between <insert company name> (hereafter referred to as "EMBARQ") and
                                        
         (hereafter referred to as "Employee" or “you”). 
 1. If you sign and return the
original of this General Release Agreement, and do not revoke it, EMBARQ will provide you Separation Pay and certain benefits for an extended period, in accordance with the terms of the Executive Severance Plan ( the “Plan”). 

Separation Pay and Benefits 
 A. At
the time EMBARQ makes its final bi-weekly payment to you under paragraph B below, EMBARQ also will pay you a cash payment equal to 80% of your target short term incentive (STI) opportunity for <insert fiscal year in which termination occurs>,
pro-rated based on the length of your separation pay period, less required payroll deductions. 
 B. EMBARQ will provide you with your full
base salary (less appropriate payroll deductions and withholdings) at your current salary, for the <insert number of weeks based on Section 4.01(a) or 4.02(a) calculation> week period beginning immediately after your last day worked and
continuing through <Date> (the “Separation Period”), which will be payable on a bi-weekly basis in accordance with EMBARQ’s normal pay cycle. These salary payments, however, will not begin to be made until one pay cycle
following seven (7) days after EMBARQ’s receipt of the signed original of this Agreement and, in any event, at least one pay cycle after your last day worked. 
  

 1 

 C. In addition, you and your dependents will continue to be eligible through <Date> for benefits as
described in the Separation Benefit Summary and subject to the terms of the applicable plans. 
 D. This Agreement does not in any way modify,
expand, limit or abrogate rights or benefits under any equity incentive plan, equity compensation plan. equity grant agreement with you, or any other employee health, welfare or benefit plan. Your rights, if any, to continued vesting of equity
awards are subject to the terms and conditions of the applicable plans and award agreements. 
 2. General Release. In consideration for the
separation pay and benefits described in paragraph 1 that EMBARQ has agreed to provide, you release and forever discharge EMBARQ and its parents, subsidiaries, affiliates, predecessors, and successors, as well as the Board of Directors of each
(collectively the “related entities”), as well as their officers, agents, directors, employees, trustees and benefit plans from any and all liability, actions, and claims, known or unknown, fixed or contingent, that you now have or may
claim to have against EMBARQ or the related entities, including any claims arising out of your employment relationship with EMBARQ or the related entities; the termination of that relationship; the conversion, grant, issuance or award of any equity,
including stock options and restricted shares; or your status as a shareholder, officer or member of a Board of Directors of any related entity,. This release includes claims arising under federal, state, or local laws prohibiting employment
discrimination or claims growing out of any legal restrictions on EMBARQ’s right to terminate its employees, including but not limited to claims arising under Title VII of the Civil Rights Act of 1964 (as amended), 42 U.S.C. § 1981, the
Age Discrimination in Employment Act (“ADEA”), the Older Worker’s Benefit Protection Act (“OWBPA”), the Employee Retirement Income Security Act (“ERISA”), the Family and Medical Leave Act, the Equal Pay Act, any
securities law or regulation, state laws against discrimination or state human rights acts, claims of wrongful discharge, claims of breach of express or implied contract, or claims under any tort or common law, including claims for attorneys’
fees. This Release does not govern claims that cannot be released by private agreement and any claims or rights that may arise after the date on which this General Release Agreement became effective. Also excluded from this General Release Agreement
is your right to file a charge with an administrative agency or participate in an agency investigation. You are, however, waiving all rights to recover money in connection with any such charge, investigation or related lawsuit. 
 Solely in clarification of the above paragraph, any obligations of EMBARQ or any insurer to indemnify you, or to advance to you expenses before a judicial or
administrative determination that you are entitled to indemnification, such obligations being memorialized or otherwise provided for in the Articles of Incorporation or Bylaws of Embarq, or in a separate written agreement, are not covered by the
release in the above paragraph and will continue to remain obligations of such persons. 
 3. Forfeiture due to Violation of Restrictive Covenants.
You understand and agree that , unless otherwise required by law, EMBARQ will cease and discontinue, effective as of the date of your violation of any restrictive covenant in Article VI of the 

  

 2 

 
Executive Severance Plan, any separation pay and benefits that otherwise would become due to you after the date of such violation. By way of illustration and
not limitation, if you make an unauthorized disclosure of proprietary information or if you engage in Competitive Employment, you will forfeit any remaining separation pay or benefits otherwise due to you during the remainder of the Separation
Period. For purposes of emphasis and as a reminder, this paragraph of the Agreement sets forth obligations already imposed on you by the Executive Severance Plan (by virtue of your execution of the Participation Agreement) and the Intellectual
Property Rights (IPR) Agreement. As noted in the Executive Severance Plan and IPR Agreement, your obligations under those agreements survive the termination of your employment. This Agreement does not supersede the IPR Agreement or Article VI of the
Executive Severance Plan. 
 Forfeiture under this paragraph is in addition to and not in place of EMBARQ’s other remedies at law or in equity for
violation of any of your restrictive covenants. 
 The terms “competitor” and “competitive employment” in this Agreement shall have the
same meaning as those same terms have in the Executive Severance Plan. 
 4. Signing and Returning this Agreement. You may not sign this
Agreement before your last day of work. If you wish to accept this Agreement, you must send it to EMBARQ at the following address: 
  

					
	 EMBARQ Address:
	  	 <insert ER Rep Address>
	  	
	 City, State:
	  	 <insert ER Rep City, State>
	  	
	 Mailstop:
	  	 <insert Mailstop>
	  	
	 Attn:
	  	 <insert ER Rep Name>
	  	

 5. Other Separation Plans and Agreements. You acknowledge and agree that the payments and benefits you
receive under this Agreement pursuant to the Executive Severance Plan replace any rights to severance pay you may have or may have had under any other separation pay plan or contract, and that you will seek no compensation or benefits from EMBARQ
under any other such plan or contract. 
 6. Choice of Law, Choice of Venue, Jury Trial and Class Action Waiver. You acknowledge and agree that this
General Release Agreement shall be governed by and is to be interpreted according to the laws of the State of Kansas. You and EMBARQ agree that any and all disputes regarding this Agreement shall be resolved by arbitration in the Kansas City,
Missouri metropolitan area in accordance with Exhibit C to the Executive Severance Plan. Any challenge to arbitrability or to an arbitration award shall be made in the Kansas State Courts in Johnson County, Kansas, or in the Federal District Court
for Kansas, and you consent to the jurisdiction of such courts. You expressly waive and relinquish the right to a trial before a jury in any action, brought in any court, concerning this General Release Agreement or any other claim against EMBARQ.
You also expressly waive the right to participate in, collect damages in, opt in or serve as a representative in any class or collective action against EMBARQ. 
  

 3 

 7. Litigation Costs. In any action relating to rights or obligations under this Agreement, each party shall pay
its own costs (including filing fees), expenses and attorney’s fees, and the parties shall split the arbitration fees equally. Excluded from this paragraph 7 is your right to challenge in good faith under the ADEA or the OWBPA the validity of
this General Release Agreement. 
 8. Acknowledgements. You acknowledge and agree that: 
  

	 	a.	the separation pay and benefits described in paragraph 1 of this General Release Agreement are in addition to whatever you would or may be entitled to receive if you did not sign
this Agreement; 

  

	 	b.	Exhibit B, attached to this General Release Agreement and provided to you, lists: the class, unit or group of individuals covered by this exit incentive program or employment
termination program; the eligibility factors for the program; any time limits applicable to the program; the job titles and ages of all individuals eligible or selected for the program; and the ages of all individuals in the same job classification
or organizational unit who were not eligible or selected for the program. 

 9. No Admission. You acknowledge and agree that this
General Release Agreement will not be construed as an admission by EMBARQ of any wrongdoing or any violation of federal, state or local, regulation or ordinance and EMBARQ disclaims any wrongdoing against you. 
 10. Severability. You acknowledge and agree that if any provision of this General Release Agreement is declared illegal or unenforceable, such provision shall
immediately become null and void, leaving the remainder of the General Release Agreement in full force and effect. 
 11. Assignability. EMBARQ may
assign its rights, liabilities and obligations under this Agreement to any subsidiary, affiliated or related entity, without notice or consent. In that event, this General Release Agreement shall bind and inure to the benefit of any assignee of or
any successor to EMBARQ. 
 12. Entire Agreement. You agree that EMBARQ has not promised you anything to induce you to enter into this Agreement other
than as specifically stated in this Agreement. EMBARQ does not have any implied obligations under this Agreement. 
 13. WARN. If EMBARQ paid you any
payments under WARN, in addition to salary separation payments under EMBARQ’s Executive Severance Plan, you agree and acknowledge that: (1) the method used to determine your rate of pay is reasonable and fairly compensates you for the
sixty day WARN Act period; (2) the EMBARQ Executive Severance Plan permits EMBARQ to deduct 

  

 4 

 
WARN Act payments from your separation pay, if applicable; and the separation pay is a voluntary and unconditional payment from EMBARQ that EMBARQ is not
legally obliged to provide unless you sign this General Release Agreement. 
 14. Revocation. You have the right to revoke this General Release
Agreement by written notice to EMBARQ, Attn: <insert ER Rep Name, ER Title> at <Insert Address and Mailstop>, within 7 calendar days after you sign it and the General Release Agreement will not become effective or enforceable until after
7 calendar days have passed. 
 Please acknowledge your acceptance of this General Release Agreement by signing this letter on or after your
last day of work and returning this letter. By signing you are acknowledging that you have carefully read and fully understand all of the provisions of this General Release Agreement (including the Notice to Employee on page 1), and that it is the
entire agreement between you and EMBARQ relating to the matters herein, including your employment and the termination of it, and you acknowledge that other than those statements in this document, you have not relied upon any representation or
statement, written or oral, in entering into this Agreement. THIS GENERAL RELEASE AGREEMENT OBLIGATES YOU TO ARBITRATE ALL DISPUTES RELATING TO IT OR ARISING UNDER IT. 
  

					
	 <insert employee name in bold>
	 		 	For <insert company name in bold>
	 (For Employee Use Only)
	 		 	(For HR Use Only)
			
	  
	 		 	  

	 Employee Signature
	 		 	Human Resource Signature
			
	  
	 		 	  

	 Employee Name (Printed or Typed)
	 		 	Human Resource Title
			
	  
	 		 	  

	 Date of Signature
	 		 	Date of Signature

  

 5 

 EXHIBIT C 
 Arbitration Provision 
 Any arbitration will be held in the Kansas City, Missouri metropolitan area (or such other
location as may be mutually agreed upon by the Employer and the Participant) and be subject to the Governing Law provision of this Plan and in accordance with the National Rules for the Resolution of Employment Disputes then in effect of the
American Arbitration Association, 9 U.S.C. § 1, et. seq, before a panel of three arbitrators, two of whom shall be selected by the Company and the Participant, respectively, and the third of whom shall be selected by the other two
arbitrators. Discovery in the arbitration will be governed by the Local Rules applicable in the United States District Court for the District of Kansas. Any award entered by the arbitrators shall be final, binding and nonappealable and judgment may
be entered thereon by either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision shall be specifically enforceable. The arbitrators shall have no authority to modify any provision of this Plan
or to award a remedy for a dispute involving this Plan other than a benefit specifically provided under or by virtue of the Plan. Each party shall be responsible for its own expenses relating to the conduct of the arbitration (including reasonable
attorneys’ fees and expenses) and shall share the fees of the American Arbitration Association and the arbitrators. 
  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]